Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HRS-4642 plus gemcitabine and nab-paclitaxel versus placebo plus chemotherapy as first-line treatment for KRAS G12D-mutant advanced pancreatic cancer
CTR20254212Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-4642 in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Started Nov 2025; status: active.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20254212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254212.